Given that IFN-γ-JAK1/2-CXCL10 signaling in keratinocytes plays a major role in MSA-specific CD8+ T cell recruitment in vitiligo, the efficacy of a topical JAK1/2 inhibitor, ruxolitinib cream, was evaluated by a prospective randomized phase 2 trial (24). This evidence concerns the gene CD8A and vitiligo.